Parkinson's Disease (PD)
Conditions
Keywords
Advanced Parkinson's Disease, Levodopa Carbidopa Intestinal Gel, Observational Study, Quality of life, Jejunal Percutaneous Endoscopic Gastrostomy
Brief summary
The aim of this study is to assess the effect of LCIG (levodopa-carbidopa intestinal gel) on HRQL (Health-Related Quality of Life) of participants and compare the Health-Related Quality of Life between participants continuing to levodopa-carbidopa intestinal gel treatments versus participants continuing on oral therapy for Parkinson's Disease.
Detailed description
Parkinson's disease (PD) is the second most common neurodegenerative disorder in the world. It can be treated sufficiently until motor complications with fluctuations of mobility and dyskinesia develop. The quality of life is relentlessly deteriorating with longer disease duration once the complications of conservative oral therapy develop. Continuous dopaminergic stimulation using Levodopa/Carbidopa Intestinal Gel (LCIG) improves the motor complications of Parkinson's disease and preliminary data suggest that also the quality of life is improved. Primary Objective is to assess the effect of LCIG on Health Related Quality of Life (HRQL) of patients according to selection criteria from German guidelines and compare improvement in HRQL between patients continuing to LCIG treatment and patients staying on oral treatment, despite being eligible according to these guidelines. In addition, current selection criteria recommended by the national guideline will be documented at baseline.
Interventions
None listed
Sponsors
AbbVie
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Eligibility for LCIG according to current version of the Summary of Product Characteristics of LCIG of the respective country (Germany, Switzerland). * Decision to treat with LCIG or other medication made by the study physician prior to any decision to approach the patient to participate in this study. * Unchanged available combinations of PD medicinal treatment for at least one week prior to study inclusion. * Patient has given written informed consent.
Exclusion criteria
* Contraindication to LCIG according to current version of the German SmPC or Swiss SmPC. * Contraindication to placement of intrajejunal PEG-J tube. * Current treatment with Deep Brain Stimulation (DBS), Apomorphine pump or LCIG * Severe dementia based on a Mini-Mental State Examination (MMSE) of \< 10 * Acute psychotic disorder (benign hallucinations or earlier psychotic episodes are not an exclusion criterion) * Depression with suicidal thoughts (earlier episodes of major depression are not an exclusion criterion) * History or presence of any condition that might interfere with absorption, distribution, metabolism, or excretion of LCIG * Drug or alcohol addiction (drug addiction: continuous or sporadic use of drugs without medical indication or with paradoxical medical indication or in inappropriate amounts. Addictive consumption of e.g. alcohol, cannabis, amphetamine, sniffing agents, cocaine, heroin, crack). Alcohol addiction male: \> 40 g/day; female: \> 30 g/day) * Illiteracy or insufficient language skills to complete the questionnaires
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the Parkinson's Disease Questionnaire (PDQ-39) summary index | From baseline to 12 months | The primary endpoint is the change in the Parkinson's Disease Questionnaire (PDQ-39) summary index from 12 months to the baseline assessment. The two treatment groups levodopa-carbidopa intestinal gel vs. Standard of Care will be compared. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in participant's motor symptoms | From Baseline to 6 and 12 months of treatment. | Activities of daily living on and off medication - Unified Parkinson's disease Rating Scale (UPDRS) part II |
| Change in participant's Healthcare Resource Utilization | From Baseline to 6 and 12 months of treatment | Frequency and severity of ON-dyskinesia (Unified Parkinson's Disease Rating Scale part IV, Complications of Therapy: Items 32, 33, 34 and 39) |
| Change in Health Related Quality of Life (HRQL) | At Baseline, 6, and 12 months of treatment | Unified Parkinson's disease Rating Scale (UPDRS) part III in the medication on state |
| Reason for transition to LCIG (or continuing oral therapy) | At Baseline, 6 and 12 month | There are no data comparing long-term HRQL of LCIG versus peroral therapy |
| Change in participant's caregiver burden | From Baseline to 6 and 12 months of treatment | Non Motor Symptoms Scale (NMSS) Total score and subdomains Cardiovascular, Sleep/Fatigue, Gastrointestinal, Urinary, Sexual functioning |
| Change in participant's non-motor symptoms | From baseline to 6 and 12 months of treatment | Non Motor Symptoms Scale (NMSS) Total score and subdomains Cardiovascular, Sleep/Fatigue, Gastrointestinal, Urinary, Sexual functioning |
Countries
Germany, Switzerland
Outcome results
None listed